HC Wainwright Expects Higher Earnings for Sensus Healthcare

Sensus Healthcare, Inc. (NASDAQ:SRTS) – HC Wainwright upped their Q4 2025 earnings estimates for Sensus Healthcare in a research report issued on Friday, May 16th. HC Wainwright analyst Y. Chen now forecasts that the company will post earnings of $0.20 per share for the quarter, up from their prior forecast of $0.19. HC Wainwright has a “Buy” rating and a $12.00 price objective on the stock. The consensus estimate for Sensus Healthcare’s current full-year earnings is $0.32 per share. HC Wainwright also issued estimates for Sensus Healthcare’s Q1 2026 earnings at $0.03 EPS, Q2 2026 earnings at $0.03 EPS, Q3 2026 earnings at $0.02 EPS and Q4 2026 earnings at $0.20 EPS.

A number of other brokerages have also recently weighed in on SRTS. Lake Street Capital reduced their price objective on shares of Sensus Healthcare from $18.00 to $13.00 and set a “buy” rating for the company in a research note on Tuesday, March 11th. Maxim Group cut their target price on shares of Sensus Healthcare from $14.00 to $10.00 and set a “buy” rating for the company in a research note on Monday.

Sensus Healthcare Trading Up 6.1%

Shares of Sensus Healthcare stock opened at $4.73 on Monday. The firm has a fifty day simple moving average of $4.61 and a 200-day simple moving average of $6.10. Sensus Healthcare has a 1-year low of $4.01 and a 1-year high of $9.33. The stock has a market capitalization of $78.02 million, a price-to-earnings ratio of 11.83 and a beta of 1.30.

Sensus Healthcare (NASDAQ:SRTS) last issued its quarterly earnings data on Thursday, May 15th. The company reported ($0.16) earnings per share for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.20). Sensus Healthcare had a return on equity of 12.60% and a net margin of 15.90%. The firm had revenue of $8.34 million during the quarter, compared to analyst estimates of $7.23 million.

Hedge Funds Weigh In On Sensus Healthcare

Several large investors have recently bought and sold shares of the stock. Trexquant Investment LP acquired a new position in Sensus Healthcare during the 1st quarter valued at $93,000. Meros Investment Management LP bought a new stake in Sensus Healthcare in the 1st quarter valued at $419,000. American Century Companies Inc. increased its holdings in Sensus Healthcare by 12.7% in the 1st quarter. American Century Companies Inc. now owns 22,440 shares of the company’s stock valued at $106,000 after buying an additional 2,520 shares during the period. Pacific Ridge Capital Partners LLC bought a new stake in Sensus Healthcare in the 1st quarter valued at $542,000. Finally, IFP Advisors Inc increased its holdings in Sensus Healthcare by 37.2% in the 1st quarter. IFP Advisors Inc now owns 18,800 shares of the company’s stock valued at $89,000 after buying an additional 5,100 shares during the period. 25.30% of the stock is currently owned by institutional investors and hedge funds.

About Sensus Healthcare

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.